Cancer is a complex disease, and for therapies to be maximally effective and tolerable, they must distinguish between normal and cancerous cells. Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells, Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting the potential of this type of agent.

Our People

Dr. Allen (Alexander) Krantz

Dr. Allen (Alexander) Krantz

Founder, CSO and COO

Allen Krantz has had an extensive career in academia and industry. From 1968 to 1980, he was a member of the Faculty at Stony Brook University, holding appointments in both the Department of Chemistry and Pharmacological Sciences. From 1981 to 1994, Dr. Krantz was Director, and then Vice-President of Research at Syntex Research Canada and held Adjunct Professorships during this period at the Universities of Toronto and Guelph while holding the title of Distinguished Scientist at the Corporation. From 1994 to 1997, Dr. Krantz served as Executive Vice President of Research at RedCell, Inc., the forerunner of ConjuChem, (TSX: CJC), and served as the Directeur Scientifique of the European office in France during the same period. He is also a Founder, and served as the inaugural President of Pharmena North America Incorporated, a privately held, biotechnology company. Dr. Krantz obtained his Masters of Science and Ph.D. degrees from Yale University.

Dr. Allen Krantz passed away in 2018 after a short illness. His many contributions will be remembered as the company continues to build upon his scientific legacy toward improving targeted cancer therapeutics.

Bill Dickie

President and CEO

Bill Dickie joins APC after serving as Co-founder, President, CEO and Director of Atreus Pharmaceuticals, a radiopharmaceutical development company in Phase II clinical trials with a medical imaging product licensed from Stanford University. Under Bill’s leadership, Atreus raised $1 million in seed capital and negotiated a $6 million strategic investment, followed by a full acquisition by Advanced Accelerator Applications International, currently a Novartis company. Previously Bill served as President, CEO and Director of Liponex Inc., (TSX:LPX) a Phase 2 company developing a novel cardiovascular drug based on technology licensed from the University of Ottawa Heart Institute. During his time as CEO, Liponex raised $10.5 Million in an IPO. Bill also spent over 25 years in management and executive roles with MDS Nordion, a large Canadian health care company. Bill’s extensive experience provides Advanced Proteome with the necessary guidance, leadership and expertise during this next, important phase of its development. Mr Dickie holds a Bachelor of Commerce degree from Carleton University and a Masters of Business Administration degree from York University.

Kenneth C. Phillippe, B. Comm, CA

Kenneth C. Phillippe, B. Comm, CA

Chief Financial Officer

Mr. Phillippe is a Chartered Accountant with over 25 years’ experience working with public companies in the capacities of director, officer, financial advisor or consultant. Mr. Phillippe obtained a Bachelor of Commerce degree from the University of British Columbia in 1976. He articled with Thorne Riddell (now KPMG) and in1982 established his own accounting practice. During the period from February, 2000 to 2008, Mr. Phillippe held several high level Executive positions including director, officer, and chair of the audit committee of Urodynamix Technologies Ltd. (TSX – (URO.V))., CFO of Columbia Goldfields Ltd. (TSX – (GOL.TO) / OTCBB –(CGDF)), as Secretary, Treasurer, CFO and Principal Accounting Officer of Amazon Goldsands Ltd.(OTCBB – (AZNG)), as well as Constitution Mining Corp (OTCC – (CMIN)). Since 2006, Mr. Phillippe has served as Chief Financial Officer of Exchequer Resource Corp. (TSX/NEX – (EXQ.H)) as well as Chief Financial Officer and Secretary of Bold Ventures Inc. (TSX – (BOL.V)).

Our Scientific Advisory Board

Dr. Greg Thurber

Faculty of Chemical Engineering and Biomedical Engineering at the University of Michigan.

Dr. Thurber’s work involves applying fundamental biotransport principles to design novel therapeutics and molecular imaging agents and developing an understanding of the critical factors that govern the distribution of agents, such as antibody-drug conjugates, in cells and tissues, to optimize their efficacies. An important point of focus is the matter of compatibility among antibody, linker, and toxin that comprise an ADC, which is central to the clinical success of this agent. Dr. Thurber, who has been a member of the Junior Faculty, Harvard Medical School/Massachusetts General Hospital, in the Radiology Department, has received several awards and is the recipient of a National Science Foundation CAREER award.

Dr. Ravi Chari

Dr. Chari has over 30 years of experience in the field of Antibody-Drug Conjugates (ADCs).  After completing a postdoctoral fellowship at Yale Medical School, he joined the Dana-Farber Cancer Institute/Harvard Medical School as a research scientist, where he initiated work on ADCs.  He, subsequently, joined ImmunoGen, where he rose to the position of Vice President – Chemistry & Biochemistry. During Dr. Chari’s career at Immunogen, his group designed novel linkers and several classes of cytotoxic payloads including maytansinoids, camptothecins and indolinobenzodiazepines. He was involved in several aspects of ADC development, including biological evaluation, and scale up and manufacture of payloads and linkers.  Dr. Chari is an inventor on 98 patents including the composition of matter patent for Kadcyla®. He is an author on more than 60 peer-reviewed publications and is a member of the Editorial board of the journals MAbs and ChemMedChem. He was appointed a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) in 2016.

Our Board

Bill Dickie

Director

Bill Dickie joins APC after serving as Co-founder, President, CEO and Director of Atreus Pharmaceuticals, a radiopharmaceutical development company in Phase II clinical trials with a medical imaging product licensed from Stanford University. Under Bill’s leadership, Atreus raised $1 million in seed capital and negotiated a $6 million strategic investment, followed by a full acquisition by Advanced Accelerator Applications International, currently a Novartis company. Previously Bill served as President, CEO and Director of Liponex Inc., (TSX:LPX) a Phase 2 company developing a novel cardiovascular drug based on technology licensed from the University of Ottawa Heart Institute. During his time as CEO, Liponex raised $10.5 Million in an IPO. Bill also spent over 25 years in management and executive roles with MDS Nordion, a large Canadian health care company. Bill’s extensive experience provides Advanced Proteome with the necessary guidance, leadership and expertise during this next, important phase of its development. Mr Dickie holds a Bachelor of Commerce degree from Carleton University and a Masters of Business Administration degree from York University.

Dr. Benjamin Krantz

Director

Benjamin Krantz MD, MBA is a fellow in hematology/oncology at New York University Langone Medical Center. He completed his residency in internal medicine at New York-Presbyterian Hospital – Columbia University Medical Center during which time he analyzed investigator intellectual property disclosures as a Columbia Technology Ventures fellow. He subsequently worked as a hospitalist and clinical/translational researcher at Memorial Sloan Kettering Cancer Center. His research has focused on biomarker and therapeutic development in pancreas ductal adenocarcinoma. He has authored peer-reviewed articles on novel therapeutics for pancreas cancer and emerging biomarkers for therapeutic selection. He has also been the architect of investigational protocols for the development of new pancreas cancer biomarkers and an early phase therapeutic candidate. Ben received a Bachelor of Arts from the University of Pennsylvania and received his Doctor of Medicine and Masters of Business Administration from Tufts University.

Paul Woodward

Director

Paul Woodward is currently President of Conation Capital Corp., and has been a frequent investor in early stage private companies. Paul is a former investment banker with over 30 years of experience in venture markets.